Clinical Trial Update: Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

An early-phase study of flavopiridol (alvocidib) in patients with relapsed or refractory lymphoma or multiple myeloma; the Phase 1/2 trial was terminated and re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• Alvocidib (Flavopiridol)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2016-08-08